| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, 2 Department of Urology, and 3 University Institute of Pathology, Aarhus University Hospital; 4 Departments of Theoretical Statistics and Mathematical Sciences, University of Aarhus; 5 Aros Applied Biotechnology, Aarhus, Denmark; and 6 Eos Biotechnology/Protein Design Labs, Fremont, California
Requests for reprints: Torben F. Ørntoft, Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark. Phone: 45-89495100; Fax: 45-89496018; E-mail: orntoft{at}ki.au.dk.
Purpose: Cancer of the urinary bladder is a common malignant disease in the western countries. The majority of patients presents with superficial tumors with a high recurrence frequency, a minor fraction of these patients experience disease progression to a muscle invasive stage. No clinical useful molecular markers exist to identify patients showing later disease progression. The purpose of this study was to identify markers of disease progression using full-genome expression analysis.
Experimental Design: We did a full-genome expression analysis (59,619 genes and expressed sequence tags) of superficial bladder tumors from 29 bladder cancer patients (13 without later disease progression and 16 with later disease progression) using high-density oligonucleotide microarrays. We used supervised learning for identification of the optimal genes for predicting disease progression. The identified genes were validated on an independent test set (74 superficial tumor samples) using in house-fabricated 60-mer oligonucleotide microarrays.
Results: We identified a 45-gene signature of disease progression. By monitoring this progression signature in an independent test set, we found a significant correlation between our classifications and the clinical outcome (P < 0.03). The genes identified as differentially expressed were involved in regulating apoptosis, cell differentiation, and cell cycle and hence may represent potential therapeutic targets.
Conclusions: Our results indicate that it may be possible to identify patients with a high risk of disease progression at an early stage using a molecular signature present already in the superficial tumors. In this way, better treatment and follow-up regimens could be assigned to patients suffering from superficial bladder cancer.
Key Words: microarray • diagnosis • prognosis • classification
This article has been cited by other articles:
|
|
 |
|
  L. Dyrskjot, M. S. Ostenfeld, J. B. Bramsen, A. N. Silahtaroglu, P. Lamy, R. Ramanathan, N. Fristrup, J. L. Jensen, C. L. Andersen, K. Zieger, et al. Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro Cancer Res., June 1, 2009; 69(11): 4851 - 4860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wang, D. S. Morris, S. A. Tomlins, R. J. Lonigro, A. Tsodikov, R. Mehra, T. J. Giordano, L. P. Kunju, C. T. Lee, A. Z. Weizer, et al. Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non-Muscle-Invasive Bladder Cancer Cancer Res., May 1, 2009; 69(9): 3810 - 3818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Rosser, L. Liu, Y. Sun, P. Villicana, M. McCullers, S. Porvasnik, P. R. Young, A. S. Parker, and S. Goodison Bladder Cancer-Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 444 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schepeler, J. T. Reinert, M. S. Ostenfeld, L. L. Christensen, A. N. Silahtaroglu, L. Dyrskjot, C. Wiuf, F. J. Sorensen, M. Kruhoffer, S. Laurberg, et al. Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer Cancer Res., August 1, 2008; 68(15): 6416 - 6424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Holyoake, P. O'Sullivan, R. Pollock, T. Best, J. Watanabe, Y. Kajita, Y. Matsui, M. Ito, H. Nishiyama, N. Kerr, et al. Development of a Multiplex RNA Urine Test for the Detection and Stratification of Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., February 1, 2008; 14(3): 742 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. X. Real p53: It Has It All, But Will It Make It to the Clinic As a Marker in Bladder Cancer? J. Clin. Oncol., December 1, 2007; 25(34): 5341 - 5344. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Als, L. Dyrskjot, H. von der Maase, K. Koed, F. Mansilla, H. E. Toldbod, J. L. Jensen, B. P. Ulhoi, L. Sengelov, K. M.E. Jensen, et al. Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4407 - 4414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dyrskjot, K. Zieger, F. X. Real, N. Malats, A. Carrato, C. Hurst, S. Kotwal, M. Knowles, P.-U. Malmstrom, M. de la Torre, et al. Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study Clin. Cancer Res., June 15, 2007; 13(12): 3545 - 3551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daugaard, T. Kirkegaard-Sorensen, M. S. Ostenfeld, M. Aaboe, M. Hoyer-Hansen, T. F. Orntoft, M. Rohde, and M. Jaattela Lens Epithelium-Derived Growth Factor Is an Hsp70-2 Regulated Guardian of Lysosomal Stability in Human Cancer Cancer Res., March 15, 2007; 67(6): 2559 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Frohlich, R. Albrechtsen, L. Dyrskjot, L. Rudkjaer, T. F. Orntoft, and U. M. Wewer Molecular Profiling of ADAM12 in Human Bladder Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7359 - 7368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aaboe, K. Birkenkamp-Demtroder, C. Wiuf, F. B. Sorensen, T. Thykjaer, G. Sauter, K. M.-E. Jensen, L. Dyrskjot, and T. Orntoft SOX4 Expression in Bladder Carcinoma: Clinical Aspects and In vitro Functional Characterization. Cancer Res., April 1, 2006; 66(7): 3434 - 3442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Carbayo, N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays J. Clin. Oncol., February 10, 2006; 24(5): 778 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zieger, L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L. Andersen, K. M.-E. Jensen, and T. F. Orntoft Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors Clin. Cancer Res., November 1, 2005; 11(21): 7709 - 7719. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
